Medication-Overuse Headache: Update on Management
Abstract
:1. Introduction
2. Epidemiology
3. Risk Factors
4. Pathophysiology
5. Diagnosis
6. Prevention
7. Treatment Strategies
7.1. Advice to Patients
7.2. Education
7.3. Drug Withdrawal
7.4. Migraine Prevention
8. Novel Treatments for Migraine
9. The Future: How to Prevent Development of an MOH
10. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Peters, G.A.; Horton, B.T. Headache: With Special Reference to the Excessive Use of Ergotamine Preparations and Withdrawal Effects. Proc. Staff Meet. Mayo Clin. 1951, 26, 153–161. [Google Scholar] [PubMed]
- Horton, B.T.; Peters, G.A. Clinical Manifestations of Excessive Use of Ergotamine Preparations and Management of Withdrawal Effect: Report of 52 Cases. Headache J. Head Face Pain 1963, 2, 214–229. [Google Scholar] [CrossRef]
- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd Edition. Cephalalgia 2018, 38, 1–211. [Google Scholar] [CrossRef] [PubMed]
- Sarchielli, P.; Corbelli, I.; Messina, P.; Cupini, L.M.; Bernardi, G.; Bono, G.; Di Piero, V.; Petolicchio, B.; Livrea, P.; Prudenzano, M.P.; et al. Psychopathological Comorbidities in Medication-overuse Headache: A Multicentre Clinical Study. Eur. J. Neurol. 2016, 23, 85–91. [Google Scholar] [CrossRef] [PubMed]
- Diener, H.-C.; Holle, D.; Solbach, K.; Gaul, C. Medication-Overuse Headache: Risk Factors, Pathophysiology and Management. Nat. Rev. Neurol. 2016, 12, 575–583. [Google Scholar] [CrossRef]
- Limmroth, V.; Katsarava, Z.; Fritsche, G.; Przywara, S.; Diener, H.-C. Features of Medication Overuse Headache Following Overuse of Different Acute Headache Drugs. Neurology 2002, 59, 1011–1014. [Google Scholar] [CrossRef]
- Cargnin, S.; Viana, M.; Sances, G.; Tassorelli, C.; Terrazzino, S. A Systematic Review and Critical Appraisal of Gene Polymorphism Association Studies in Medication-Overuse Headache. Cephalalgia 2018, 38, 1361–1373. [Google Scholar] [CrossRef]
- Lipton, R.B.; Croop, R.; Stock, E.G.; Stock, D.A.; Morris, B.A.; Frost, M.; Dubowchik, G.M.; Conway, C.M.; Coric, V.; Goadsby, P.J. Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine. N. Engl. J. Med. 2019, 381, 142–149. [Google Scholar] [CrossRef] [PubMed]
- Lipton, R.B.; Dodick, D.W.; Ailani, J.; Lu, K.; Finnegan, M.; Szegedi, A.; Trugman, J.M. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. JAMA 2019, 322, 1887. [Google Scholar] [CrossRef]
- Lipton, R.B.; Croop, R.; Stock, D.A.; Madonia, J.; Forshaw, M.; Lovegren, M.; Mosher, L.; Coric, V.; Goadsby, P.J. Safety, Tolerability, and Efficacy of Zavegepant 10 Mg Nasal Spray for the Acute Treatment of Migraine in the USA: A Phase 3, Double-Blind, Randomised, Placebo-Controlled Multicentre Trial. Lancet Neurol. 2023, 22, 209–217. [Google Scholar] [CrossRef]
- Goadsby, P.J.; Wietecha, L.A.; Dennehy, E.B.; Kuca, B.; Case, M.G.; Aurora, S.K.; Gaul, C. Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Lasmiditan for Acute Treatment of Migraine. Brain 2019, 142, 1894–1904. [Google Scholar] [CrossRef] [PubMed]
- Tepper, S.J.; Lipton, R.B.; Silberstein, S.D.; Kudrow, D.; Ashina, M.; Reuter, U.; Dodick, D.W.; Wang, A.; Cheng, S.; Klatt, J.; et al. Long-term Efficacy and Safety of Erenumab in Patients with Chronic Migraine and Acute Medication Overuse: A Subgroup Analysis. Headache J. Head Face Pain 2023, 63, 730–742. [Google Scholar] [CrossRef] [PubMed]
- Silberstein, S.D.; Cohen, J.M.; Seminerio, M.J.; Yang, R.; Ashina, S.; Katsarava, Z. The Impact of Fremanezumab on Medication Overuse in Patients with Chronic Migraine: Subgroup Analysis of the HALO CM Study. J. Headache Pain 2020, 21, 114. [Google Scholar] [CrossRef] [PubMed]
- Dodick, D.W.; Doty, E.G.; Aurora, S.K.; Ruff, D.D.; Stauffer, V.L.; Jedynak, J.; Dong, Y.; Pearlman, E.M. Medication Overuse in a Subgroup Analysis of Phase 3 Placebo-Controlled Studies of Galcanezumab in the Prevention of Episodic and Chronic Migraine. Cephalalgia 2021, 41, 340–352. [Google Scholar] [CrossRef] [PubMed]
- Marmura, M.J.; Diener, H.; Cowan, R.P.; Tepper, S.J.; Diamond, M.L.; Starling, A.J.; Hirman, J.; Mehta, L.; Brevig, T.; Cady, R. Preventive Migraine Treatment with Eptinezumab Reduced Acute Headache Medication and Headache Frequency to below Diagnostic Thresholds in Patients with Chronic Migraine and Medication-overuse Headache. Headache J. Head Face Pain 2021, 61, 1421–1431. [Google Scholar] [CrossRef]
- Ailani, J.; Lipton, R.B.; Goadsby, P.J.; Guo, H.; Miceli, R.; Severt, L.; Finnegan, M.; Trugman, J.M.; ADVANCE Study Group. Atogepant for the Preventive Treatment of Migraine. N. Engl. J. Med. 2021, 385, 695–706. [Google Scholar] [CrossRef]
- Slomski, A. Oral Rimegepant Safe, Effective for Migraine Prevention. JAMA 2021, 325, 713. [Google Scholar] [CrossRef]
- Diener, H.-C.; Limmroth, V. Medication-Overuse Headache: A Worldwide Problem. Lancet Neurol. 2004, 3, 475–483. [Google Scholar] [CrossRef]
- Westergaard, M.L.; Hansen, E.H.; Glümer, C.; Olesen, J.; Jensen, R.H. Definitions of Medication-Overuse Headache in Population-Based Studies and Their Implications on Prevalence Estimates: A Systematic Review. Cephalalgia 2014, 34, 409–425. [Google Scholar] [CrossRef] [PubMed]
- Kristoffersen, E.S.; Lundqvist, C. Medication-Overuse Headache: Epidemiology, Diagnosis and Treatment. Ther. Adv. Drug Saf. 2014, 5, 87–99. [Google Scholar] [CrossRef] [PubMed]
- Shand, B.; Goicochea, M.T.; Valenzuela, R.; Fadic, R.; Jensen, R.; Tassorelli, C.; Nappi, G.; the COMOESTAS CONSORTIUM. Clinical and Demographical Characteristics of Patients with Medication Overuse Headache in Argentina and Chile: Analysis of the Latin American Section of COMOESTAS Project. J. Headache Pain 2015, 16, 83. [Google Scholar] [CrossRef] [PubMed]
- Bahra, A.; Walsh, M.; Menon, S.; Goadsby, P.J. Does Chronic Daily Headache Arise De Novo in Association with Regular Use of Analgesics? Headache J. Head Face Pain 2003, 43, 179–190. [Google Scholar] [CrossRef] [PubMed]
- Bigal, M.E.; Serrano, D.; Buse, D.; Scher, A.; Stewart, W.F.; Lipton, R.B. Acute Migraine Medications and Evolution from Episodic to Chronic Migraine: A Longitudinal Population-Based Study. Headache J. Head Face Pain 2008, 48, 1157–1168. [Google Scholar] [CrossRef] [PubMed]
- Bigal, M.E.; Lipton, R.B. Excessive Acute Migraine Medication Use and Migraine Progression. Neurology 2008, 71, 1821–1828. [Google Scholar] [CrossRef] [PubMed]
- Bailey, S.C.; Pack, A.P.; Zuleta, A.; Huang, W.; Herman, M.P.; Kymes, S.M.; Fiore, D.; Curran, Y. Association between awareness and knowledge of medication-overuse headache with medication-taking behavior among adults with migraine. PLoS ONE 2024, 19, e0306264. [Google Scholar] [CrossRef]
- Cevoli, S.; Sancisi, E.; Grimaldi, D.; Pierangeli, G.; Zanigni, S.; Nicodemo, M.; Cortelli, P.; Montagna, P. Family History for Chronic Headache and Drug Overuse as a Risk Factor for Headache Chronification. Headache J. Head Face Pain 2009, 49, 412–418. [Google Scholar] [CrossRef]
- Calabresi, P.; Cupini, L.M. Medication-Overuse Headache: Similarities with Drug Addiction. Trends Pharmacol. Sci. 2005, 26, 62–68. [Google Scholar] [CrossRef]
- Khokhar, J.Y.; Ferguson, C.S.; Zhu, A.Z.X.; Tyndale, R.F. Pharmacogenetics of Drug Dependence: Role of Gene Variations in Susceptibility and Treatment. Annu. Rev. Pharmacol. Toxicol. 2010, 50, 39–61. [Google Scholar] [CrossRef] [PubMed]
- Bongsebandhu-phubhakdi, S.; Srikiatkhachorn, A. Pathophysiology of Medication-Overuse Headache: Implications from Animal Studies. Curr. Pain Headache Rep. 2012, 16, 110–115. [Google Scholar] [CrossRef]
- Melo-Carrillo, A.; Strassman, M.; Nir, R.-R.; Schain, A.J.; Nosed, R.; Stratton, J.; Burstein, R. Fremanezumab—A humanized monoclonal anti-CGRP antibody—Inhibits thinly myelinated (Aδ) but not unmyelinated (C) meningeal nociceptors. J. Neurosci. 2017, 37, 10587–10596. [Google Scholar] [CrossRef]
- Supornsilpchai, W.; Le Grand, S.M.; Srikiatkhachorn, A. Involvement of Pro-Nociceptive 5-HT 2A Receptor in the Pathogenesis of Medication-Overuse Headache. Headache J. Head Face Pain 2010, 50, 185–197. [Google Scholar] [CrossRef] [PubMed]
- Green, A.L.; Gu, P.; De Felice, M.; Dodick, D.; Ossipov, M.H.; Porreca, F. Increased Susceptibility to Cortical Spreading Depression in an Animal Model of Medication-Overuse Headache. Cephalalgia 2014, 34, 594–604. [Google Scholar] [CrossRef] [PubMed]
- Becerra, L.; Bishop, J.; Barmettler, G.; Xie, Y.; Navratilova, E.; Porreca, F.; Borsook, D. Triptans Disrupt Brain Networks and Promote Stress-Induced CSD-like Responses in Cortical and Subcortical Areas. J. Neurophysiol. 2016, 115, 208–217. [Google Scholar] [CrossRef] [PubMed]
- Jang, Y.E.; Cho, E.Y.; Choi, H.Y.; Kim, S.M.; Park, H.Y. Diagnostic Neuroimaging in Headache Patients: A Systematic Review and Meta-Analysis. Psychiatry Investig. 2019, 16, 407–417. [Google Scholar] [CrossRef] [PubMed]
- Clarke, C.E.; Edwards, J.; Nicholl, D.J.; Sivaguru, A. Imaging Results in a Consecutive Series of 530 New Patients in the Birmingham Headache Service. J. Neurol. 2010, 257, 1274–1278. [Google Scholar] [CrossRef]
- Moraes Alves, A.L.; Silva, I.K.; Paula Lemos, P.H.; Lomachinsky Torres, V.; Crevanzi Arraes, E.; Sampaio Rocha-Filho, P.A. FRAMES Protocol versus Simple Advice for Medication-Overuse Headache: A Prospective, Randomized, Controlled Clinical Trial. Acta Neurol. Belg. 2021, 121, 1259–1264. [Google Scholar] [CrossRef]
- Couch, J.R. Can medication overuse headache be treated by abrupt withdrawal of the overused agent? Nat. Clin. Pract. Neurol. 2006, 2, 654–655. [Google Scholar] [CrossRef]
- Kristoffersen, E.S.; Straand, J.; Vetvik, K.G.; Benth, J.Š.; Russell, M.B.; Lundqvist, C. Brief Intervention for Medication-Overuse Headache in Primary Care. The BIMOH Study: A Double-Blind Pragmatic Cluster Randomised Parallel Controlled Trial. J. Neurol. Neurosurg. Psychiatry 2015, 86, 505–512. [Google Scholar]
- Rossi, P.; Faroni, J.V.; Nappi, G. Short-Term Effectiveness of Simple Advice as a Withdrawal Strategy in Simple and Complicated Medication Overuse Headache: Advice Alone as a Withdrawal Strategy for MOH. Eur. J. Neurol. 2011, 18, 396–401. [Google Scholar] [CrossRef] [PubMed]
- Grande, R.B.; Aaseth, K.; Benth, J.Š.; Lundqvist, C.; Russell, M.B. Reduction in Medication-overuse Headache after Short Information. The Akershus Study of Chronic Headache. Eur. J. Neurol. 2011, 18, 129–137. [Google Scholar] [CrossRef]
- Katsarava, Z.; Fritsche, G.; Muessig, M.; Diener, H.C.; Limmroth, V. CME Clinical Features of Withdrawal Headache Following Overuse of Triptans and Other Headache Drugs. Neurology 2001, 57, 1694–1698. [Google Scholar] [CrossRef] [PubMed]
- Zeeberg, P.; Olesen, J.; Jensen, R. Discontinuation of Medication Overuse in Headache Patients: Recovery of Therapeutic Responsiveness. Cephalalgia 2006, 26, 1192–1198. [Google Scholar] [CrossRef] [PubMed]
- Carlsen, L.N.; Munksgaard, S.B.; Jensen, R.H.; Bendtsen, L. Complete Detoxification Is the Most Effective Treatment of Medication-Overuse Headache: A Randomized Controlled Open-Label Trial. Cephalalgia 2018, 38, 225–236. [Google Scholar] [CrossRef] [PubMed]
- Rossi, P.; Faroni, J.V.; Tassorelli, C.; Nappi, G. Advice Alone versus Structured Detoxification Programmes for Complicated Medication Overuse Headache (MOH): A Prospective, Randomized, Open-Label Trial. J. Headache Pain 2013, 14, 10. [Google Scholar] [CrossRef] [PubMed]
- De Goffau, M.J.; Klaver, A.R.E.; Willemsen, M.G.; Bindels, P.J.E.; Verhagen, A.P. The Effectiveness of Treatments for Patients with Medication Overuse Headache: A Systematic Review and Meta-Analysis. J. Pain 2017, 18, 615–627. [Google Scholar] [CrossRef] [PubMed]
- Rossi, P.; Lorenzo, C.D.; Faroni, J.; Cesarino, F.; Nappi, G. Advice Alone vs. Structured Detoxification Programmes for Medication Overuse Headache: A Prospective, Randomized, Open-Label Trial in Transformed Migraine Patients with Low Medical Needs. Cephalalgia 2006, 26, 1097–1105. [Google Scholar] [CrossRef] [PubMed]
- Williams, D.R.; Stark, R.J. Intravenous lignocaine (lidocaine) infusion for the treatment of chronic daily headache with substantial medication overuse. Cephalalgia 2003, 23, 963–971. [Google Scholar] [CrossRef]
- Arab, A.; Khoshbin, M.; Karimi, E.; Saberian, G.; Saadatnia, M.; Khorvash, F. Effects of Greater Occipital Nerve Block with Local Anesthetic and Triamcinolone for Treatment of Medication Overuse Headache: An Open-Label, Parallel, Randomized, Controlled Clinical Trial. Neurol. Sci. 2022, 43, 549–557. [Google Scholar] [CrossRef]
- Bendtsen, L.; Munksgaard, S.; Tassorelli, C.; Nappi, G.; Katsarava, Z.; Lainez, M.; Leston, J.; Fadic, R.; Spadafora, S.; Stoppini, A.; et al. COMOESTAS Consortium. Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia 2014, 34, 426–433. [Google Scholar] [CrossRef]
- Carlsen, L.N.; Rouw, C.; Westergaard, M.L.; Nielsen, M.; Munksgaard, S.B.; Bendtsen, L.; Jensen, R.H. Treatment of Medication Overuse Headache: Effect and Predictors after 1 Year—A Randomized Controlled Trial. Headache J. Head Face Pain 2021, 61, 1112–1122. [Google Scholar] [CrossRef]
- Schwedt, T.J.; Hentz, J.G.; Sahai-Srivastava, S.; Murinova, N.; Spare, N.M.; Treppendahl, C.; Martin, V.T.; Birlea, M.; Digre, K.; Watson, D.; et al. Patient-Centered Treatment of Chronic Migraine with Medication Overuse: A Prospective, Randomized, Pragmatic Clinical Trial. Neurology 2022, 98, e1409–e1421. [Google Scholar] [CrossRef] [PubMed]
- Silberstein, S.D.; Lipton, R.B.; Dodick, D.W.; Freitag, F.G.; Ramadan, N.; Mathew, N.; Brandes, J.L.; Bigal, M.; Saper, J.; Ascher, S.; et al. Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial. Headache J. Head Face Pain 2007, 47, 170–180. [Google Scholar] [CrossRef]
- Silberstein, S.D.; Blumenfeld, A.M.; Cady, R.K.; Turner, I.M.; Lipton, R.B.; Diener, H.-C.; Aurora, S.K.; Sirimanne, M.; DeGryse, R.E.; Turkel, C.C.; et al. OnabotulinumtoxinA for Treatment of Chronic Migraine: PREEMPT 24-Week Pooled Subgroup Analysis of Patients Who Had Acute Headache Medication Overuse at Baseline. J. Neurol. Sci. 2013, 331, 48–56. [Google Scholar] [CrossRef] [PubMed]
- Tepper, S.J.; Diener, H.-C.; Ashina, M.; Brandes, J.L.; Friedman, D.I.; Reuter, U.; Cheng, S.; Nilsen, J.; Leonardi, D.K.; Lenz, R.A.; et al. Erenumab in Chronic Migraine with Medication Overuse: Subgroup Analysis of a Randomized Trial. Neurology 2019, 92, e2309–e2320. [Google Scholar] [CrossRef]
- Diener, H.; Marmura, M.J.; Tepper, S.J.; Cowan, R.; Starling, A.J.; Diamond, M.L.; Hirman, J.; Mehta, L.; Brevig, T.; Sperling, B.; et al. Efficacy, Tolerability, and Safety of Eptinezumab in Patients with a Dual Diagnosis of Chronic Migraine and Medication-overuse Headache: Subgroup Analysis of PROMISE-2. Headache 2021, 61, 125–136. [Google Scholar] [CrossRef]
- Curone, M.; Tullo, V.; Didier, H.A.; Bussone, G. Overview on Effectiveness of Erenumab, Fremanezumab, and Galcanezumab in Reducing Medication Overuse Headache in Chronic Migraine Patients. Neurol. Sci. 2022, 43, 5759–5761. [Google Scholar] [CrossRef] [PubMed]
- Krymchantowski, A.V.; Jevoux, C.; Krymchantowski, A.G.; Silva-Néto, R.P. Monoclonal Antibodies for Chronic Migraine and Medication Overuse Headache: A Real-World Study. Front. Neurol. 2023, 14, 1129439. [Google Scholar] [CrossRef]
- Krymchantowski, A.; Jevoux, C.; Krymchantowski, A.G.; Silva-Néto, R.P. Medication Overuse Headache, Chronic Migraine and Monoclonal Antibodies Anti-CGRP: A Real-World Study. Clin. Neuropharmacol. 2023, 46, 181–185. [Google Scholar] [CrossRef]
- Salvatore, C.A.; Mallee, J.J.; Bell, I.M.; Zartman, C.B.; Williams, T.M.; Koblan, K.S.; Kane, S.A. Identification and Pharmacological Characterization of Domains Involved in Binding of CGRP Receptor Antagonists to the Calcitonin-like Receptor. Biochemistry 2006, 45, 1881–1887. [Google Scholar] [CrossRef]
- Rubio-Beltrán, E.; Labastida-Ramírez, A.; Haanes, K.A.; Van Den Bogaerdt, A.; Bogers, A.J.J.C.; Zanelli, E.; Meeus, L.; Danser, A.H.J.; Gralinski, M.R.; Senese, P.B.; et al. Characterization of Binding, Functional Activity, and Contractile Responses of the Selective 5-HT 1F Receptor Agonist Lasmiditan. Br. J. Pharmacol. 2019, 176, 4681–4695. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Koonalintip, P.; Phillips, K.; Wakerley, B.R. Medication-Overuse Headache: Update on Management. Life 2024, 14, 1146. https://doi.org/10.3390/life14091146
Koonalintip P, Phillips K, Wakerley BR. Medication-Overuse Headache: Update on Management. Life. 2024; 14(9):1146. https://doi.org/10.3390/life14091146
Chicago/Turabian StyleKoonalintip, Prut, Katherine Phillips, and Benjamin R. Wakerley. 2024. "Medication-Overuse Headache: Update on Management" Life 14, no. 9: 1146. https://doi.org/10.3390/life14091146